Episode 2

26 min

Aug 9, 2026

‘MPN - does spleen size REALLY matter?’ w. Claire Harrison

‘MPN - does spleen size REALLY matter?’ w. Claire Harrison

In this episode, Prof. Claire Harrison discusses the central role of the spleen in myelofibrosis - from its biology and clinical significance to its dominance as trial endpoint. The conversation explores how spleen responses relate to symptoms, survival, disease heterogeneity, and the future of endpoint selection in MPN clinical trials.

Guest

Prof. Claire Harrison

Claire Harrison graduated and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy chief medical officer.

The focus of her clinical work is myeloproliferative neoplasms (MPN), key areas of interest are clinical trials and associated translational research. Her work has led to the approval of new therapies such a ruxolitinib, fedratinib, momelotinib and pacritinib. In the past 10 years she has published widely (>300 academic articles).

In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.

More episodes

  • Episode 4

    29 min

    Oct 4, 2026

    ‘CAR T cells CURE and CAUSE cancer’ w. Roni Shouval

    In this episode, together with Roni Shouval, we discuss the evolution of CAR T cells and their potential for cure: what does cure actually mean? We will also touch the hot topic of their potential for causing cancer, how likely it is and what this means for patients and clinicians alike.

    Roni Shouval

  • Episode 3

    27 min

    Sep 6, 2026

    ‘Conditioning intensity MATTERS for allogeneic transplant’ w. C. Craddock

    In this episode Prof. Charles Craddock discusses the major aims of conditioning regimens prior to allogeneic stem cell transplantation and how to select proper intensity of the regimen to balance Graft versus Leukemia effect and regimen related toxicity.

    Prof. Charles Craddock

  • Episode 1

    23 min

    Jul 12, 2026

    ‘PTCy – for ALL donors?’ w. Leo Luznik

    In this episode Prof. Leo Luznik will describe how post-transplant cyclophosphamide as effective GvHD prophylaxis was detected and used after haploidentical allogeneic transplantation and its current and future role in HLA identical sibling, as well as in matched and mismatched unrelated stem cell transplantation.

    0.5 CME Credits

    Prof. Leo Luznik